ML-7 hydrochloride is a selective myosin light chain kinase (IC50 = 300nM) [1]. ML-7 hydrochloride competitively inhibits the ATP binding activity of myosin light chain kinase (MLCK), thereby inhibiting MLC phosphorylation and regulating cytoskeleton, contraction and migration behavior [2]. ML-7 hydrochloride is used in research on cell biology, oncology, vascular physiology [3-4].
In leukocyte, ML-7 hydrochloride (20μM; 24h) treatment induces lysosome-mediated cell death in neutrophils from patients with sepsis [5]. In Klebsiella pneumoniae, ML-7 hydrochloride (64μg/mL; 24h) treatment could enhance the killing activity of tigecycline [6]. In oeFOXP2 cells, ML-7 hydrochloride (40μM; 48h) administration markedly increased the proliferation of cell [7].
In Lewis lung carcinoma cell subcutaneous tumor mice model, ML-7 hydrochloride (0.25mg/kg; ip; 7d) pretreated tumors were significantly smaller than those pretreated with vehicle control [8]. In the mouse model treated with trimellitic anhydride, injection of ML-7 hydrochloride (1mg/kg; ip; 5d) significantly inhibited the exacerbation of scratching behavior induced by immobilization stress [9].
References:
[1]. Simoes RL, Fierro IM. Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog. The Journal of Immunology. 2005 Aug 1; 175(3): 1843-1850.
[2]. Ran Q, Li A, Tan Y, et al. Action and therapeutic targets of myosin light chain kinase, an important cardiovascular signaling mechanism. Pharmacological Research. 2024 Jun 27: 107276.
[3]. Xiong Y, Wang C, Shi L, et al. Myosin light chain kinase: a potential target for treatment of inflammatory diseases. Frontiers in pharmacology. 2017 May 23; 8: 292.
[4]. Gu LZ, Hu WY, Antic N, et al. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. European journal of cancer. 2006 May 1; 42(7): 948-957.
[5]. Wu J, Barkat MQ, Su J, et al. Inhibition of non-muscular myosin light chain kinase accelerates the clearance of inflammatory cells by promoting the lysosome-mediated cell death. Biomedicine & Pharmacotherapy. 2024 Jan 1; 170: 115986.
[6]. Sun L, Sun L, Li X, et al. A novel tigecycline adjuvant ML-7 reverses the susceptibility of tigecycline-resistant Klebsiella pneumoniae. Frontiers in Cellular and Infection Microbiology. 2022 Jan 5; 11: 809542.
[7]. Chang S. Effect of forkhead box protein P2-mediated activation of myosin light-chain kinase on the invasion and migration of endometrial cancer cells. CytoJournal. 2025 May 14; 22: 54.
[8]. Kim YE, Gwak SH, Hong BJ, et al. Effects of ultra-high doserate FLASH irradiation on the tumor microenvironment in Lewis lung carcinoma: role of myosin light chain. International Journal of Radiation Oncology* Biology* Physics. 2021 Apr 1;109(5):1440-1453.
[9]. Cho DE, Hong JP, Kim Y, et al. Role of gut-derived bacterial lipopolysaccharide and peripheral TLR4 in immobilization stress-induced itch aggravation in a mouse model of atopic dermatitis. Scientific reports. 2024 Mar 15; 14(1): 6263.
ML-7 hydrochloride是一种选择性肌球蛋白轻链激酶（IC50 = 300nM） [1]。ML-7 hydrochloride竞争性抑制肌球蛋白轻链激酶（MLCK）的ATP结合活性，从而抑制MLC磷酸化并调节细胞骨架、收缩和迁移行为 [2]。ML-7 hydrochloride用于细胞生物学、肿瘤学和血管生理学的研究 [3-4]。
在白细胞中，ML-7 hydrochloride（20μM；24h）处理可诱导脓毒症患者中性粒细胞发生溶酶体介导的细胞死亡 [5]。在肺炎克雷伯菌中，ML-7盐酸盐（64μg/mL；24h）处理可增强替加环素的杀灭活性 [6]。在oeFOXP2细胞中，给予ML-7 hydrochloride（40μM；48h）可显著增加细胞增殖 [7]。
在Lewis肺癌细胞皮下移植瘤小鼠模型中，ML-7 hydrochloride（0.25mg/kg；ip；7d）预处理的肿瘤显著小于用载体对照组预处理的肿瘤 [8]。在用偏苯三酸酐处理的小鼠模型中，注射ML-7 hydrochloride（1mg/kg；ip；5d）可显著抑制因束缚应激引起的抓挠行为的加剧 [9]。